EU regulators to investigate Aspen's drug prices for cancer

BRUSSELS (Reuters) - EU antitrust regulators will investigate whether South Africa's Aspen Pharmacare pricing practices for five of its cancer medicines violate the bloc's rules against companies abusing their market power.